A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).
Phase 1
Recruiting
- Conditions
- Acute myeloid leukemia or myelodysplastic syndrome of high risk group,that has come back after treatment or cannot be cured or treated by anyother known therapies.MedDRA version: 21.0Level: LLTClassification code: 10060558Term: Acute myeloid leukemia recurrent Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10081514Term: Acute myeloid leukemia refractory Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-503869-34-00
- Lead Sponsor
- Celgene Corp.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): ;Main Objective: ;Secondary Objective:
- Secondary Outcome Measures
Name Time Method